Brief: Keros Announces US FDA Orphan Drug Designation Granted To KER-065
20/08/2025 16:40
Aug 20 (Reuters) - Keros Therapeutics Inc KROS.O: KEROS ANNOUNCES U.S. FDA ORPHAN DRUG DESIGNATION GRANTED TO KER-065 FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY Source text: ID:nGNX1bj2NC Further company coverage: KROS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Keros Therapeutics
See all newsBrief: Keros Therapeutics May Offer Up To $350 Million Of Securities - SEC Filing
Keros Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Keros Therapeutics Q2 net loss narrows on lower expenses
Brief: Keros Therapeutics - Keith Regnante Resigns As CFO
Keros Therapeutics posts Q1 net loss as license revenue drops